Thapsigargin: key to new host-directed coronavirus antivirals?
Trends Pharmacol Sci
; 43(7): 557-568, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1796053
ABSTRACT
Despite the great success of vaccines that protect against RNA virus infections, and the development and clinical use of a limited number of RNA virus-specific drugs, there is still an urgent need for new classes of antiviral drugs against circulating or emerging RNA viruses. To date, it has proved difficult to efficiently suppress RNA virus replication by targeting host cell functions, and there are no approved drugs of this type. This opinion article discusses the recent discovery of a pronounced and sustained antiviral activity of the plant-derived natural compound thapsigargin against enveloped RNA viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza A virus. Based on its mechanisms of action, thapsigargin represents a new prototype of compounds with multimodal host-directed antiviral activity.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Coronavirus del Síndrome Respiratorio de Oriente Medio
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudio pronóstico
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Trends Pharmacol Sci
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
J.tips.2022.04.004
Similares
MEDLINE
...
LILACS
LIS